文献速递MDS 与骨髓增殖性肿瘤

更广阔的视角:骨髓增生异常综合征二十年临床试验分析

The wider perspective: twenty years of clinical trials in myelodysplastic syndromes.
PubMed 文献 · Br J Haematol · 2021-10-10

该研究检索2000至2020年临床试验注册库中骨髓增生异常综合征(MDS)试验,识别384种药物在426项I期、430项II期和48项III期试验中接受评估。III期试验及药物成功率低,MDS试验完成时间显著长于平均临床试验,52%药物未在MDS专用I期试验中评估,且常未纳入生活质量终点。

要点

  • MDS临床试验中III期成功率低,且试验完成时间显著长于平均水平。
  • 52%的MDS药物未在MDS专用I期试验中评估,影响后续开发效率。
  • MDS试验常未纳入生活质量终点,对老年患者尤为重要。

核心结论

  • MDS领域可用药物匮乏与III期成功率低、试验完成时间长及I期评估不足相关。
  • 研究提出改进MDS临床研究的框架,以期增加可用药物数量。

研究设计与样本

  • 检索clinicaltrials.gov和clinicaltrialsregister.eu,纳入2000至2020年MDS试验。
  • 共识别384种药物,涉及426项I期、430项II期和48项III期试验。

主要发现

  • III期试验及药物的成功率低。
  • MDS试验完成时间显著长于平均临床试验。
  • MDS专用I期试验开展时成功率较高,但52%的药物未在MDS的I期试验中评估。
  • MDS试验常未纳入生活质量终点。

临床怎么用

  • 开展MDS药物研发时应优先完成MDS专用I期评估,并关注试验完成效率。
  • 试验设计应纳入生活质量终点,尤其针对老年MDS患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most patients with myelodysplastic syndromes (MDS) require therapeutic intervention. However, there are few approved treatments for MDS. To explore reasons, we searched clinicaltrials.gov and clinicaltrialsregister.eu for MDS trials from 2000 to 2020. We assessed which agents were under investigation and analysed clinical trial characteristics and continuation rates from phase I to II to III to approval. As such, we identified 384 unique agents in 426 phase I, 430 phase II and 48 phase III trials. Success rates for phase III trials and agents were low, and MDS trials took markedly longer to complete than the average clinical trial. Although success rates were higher when MDS-specific phase I trials were conducted, 52% of the agents had not been evaluated in a phase I trial for MDS. MDS trials often failed to include quality of life, an especially important outcome for older MDS patients. Our work identifies factors potentially contributing to the paucity of available agents for MDS. We suggest a framework to improve clinical research in MDS that might ultimately augment the number of available agents.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Duetz C, Cucchi DGJ, Polak TB, et al. The wider perspective: twenty years of clinical trials in myelodysplastic syndromes. Br J Haematol. 2021. PMID: 34632583. doi:10.1111/bjh.17892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。